Contents

Search

mafenide (Sulfamylon)

Withdrawn from U.S. market by maker Viatris [2] Indications: - antibacterial burn cream containing mafenid with good penetration for deep injury - sunburn Adverse effects: - bicarbonate-diuresis resulting in metabolic acidosis Mechanism of action: - carbonic anhydrase inhibitor

Interactions

drug interactions drug adverse effects of sulfonamides

General

dermatologic agent sulfonamide

Database Correlations

PUBCHEM correlations

References

  1. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 2558
  2. Brennan Z Viatris withdraws accelerated approval for topical antimicrobial 24 years later. EndpointsNews. Nov 29, 2022 https://endpts.com/viatris-withdraws-accelerated-approval-for-topical-antimicrobial-24-years-later/